PARCT: Trial of Atezolizumab in Relapsed/Refractory Cutaneous T Cell Lymphoma (CTCL)
Clinical trial NCT03357224 · TERMINATED
Trial details
- NCT number
- NCT03357224
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-09-24
- Primary completion
- 2021-03-11
- Enrollment
- 26
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.